Purpose

This study will determine the impact of selective kappa-opioid receptor (KOPr) antagonism with the novel Lilly compound OpRA Kappa (LY2456302) in persons at specific stages in cocaine addiction trajectory compared to normal healthy volunteers. KOPr receptors (encoded by gene OPRK1) and their endogenous neuropeptide ligands (the dynorphins encoded by gene PDYN) they are upregulated in addictive diseases and in other neuropsychiatric diseases. This upregulation may be due to chronic exposure to drugs of abuse such as cocaine due to stress exposure or as part of the etiology of the disease. Increased signaling through KOPr is thought to result in a relapse-prone state and to cause dysphoria / anhedonia in humans. KOPr antagonists thus represent a novel potential therapeutic strategy in cocaine addiction and related depressive symptoms a disease associated with massive public health morbidity and for which no pharmacotherapies exist

Condition

Eligibility

Eligible Ages
Between 18 and 65
Eligible Genders
1
Accepts Healthy Volunteers
Yes

Study Design

Phase
early Phase 1
Study Type
Observational

More Details

Status
Recruiting
Sponsor
Rockefeller University

Study Contact

Recruitment Office
8007822737
rucares@rockefeller.edu

Notice

Study information shown on this site is derived from this institution's local clinical trials team. The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.